Literature DB >> 29344738

Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia.

Takashi Kondo1, Toshimichi Yasuda2, Keiko Mukaida3, Sachiko Otsuki4, Rieko Kanzaki4, Hirotsugu Miyoshi4, Hiroshi Hamada2, Ichizo Nishino5, Masashi Kawamoto2.   

Abstract

PURPOSE: The aim of this study was to analyze the genetic and functional role of a novel RYR1 variant c.251 C > T (p.Thr84Met) identified in a patient with muscle weakness demonstrating MH susceptibility.
METHODS: DNA testing of family members was conducted for assessment of pathogenicity of the genetic variant. For functional analysis, Ca2+ measurement using patient-derived myotubes and p.Thr84Met RYR1-transfected human embryonic kidney (HEK)-293 cells was performed to evaluate reactivity to RYR1 activators. The half-maximal effective concentration (EC50) values of two RYR1 activators, caffeine and 4-chloro-m-cresol (4CmC), were calculated from the acquired dose-response curves. The EC50 was compared between two groups: for myotubes, the control group and the patient, and for HEK-293 cells, WT and p.Thr84Met.
RESULTS: Dose-response curves for caffeine and 4CmC were shifted to the left in both myotubes and HEK-293 cells compared to controls. The 50% effective concentration values for caffeine and 4CmC were significantly lower in both myotubes and HEK-293 cells compared to controls (P < 0.001 for all comparisons).
CONCLUSIONS: Our results of functional testing indicated RYR1 hypersensitivity to caffeine and 4CmC. We conclude that the genetic variant was associated with MH susceptibility.

Entities:  

Keywords:  Calcium release; Malignant hyperthermia; Mutation; Ryanodine receptor

Mesh:

Substances:

Year:  2018        PMID: 29344738     DOI: 10.1007/s00540-018-2451-6

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  29 in total

1.  The spectrum of pathology in central core disease.

Authors:  C A Sewry; C Müller; M Davis; J S M Dwyer; J Dove; G Evans; R Schröder; D Fürst; T Helliwell; N Laing; R C M Quinlivan
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

Review 2.  Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca(2+) release channels?

Authors:  Robert T Dirksen; Guillermo Avila
Journal:  Trends Cardiovasc Med       Date:  2002-07       Impact factor: 6.677

3.  Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.

Authors:  Carlos A Ibarra M; Shiwen Wu; Kumiko Murayama; Narihiro Minami; Yasuko Ichihara; Hirosato Kikuchi; Satoru Noguchi; Yukiko K Hayashi; Ryoichi Ochiai; Ichizo Nishino
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

Review 4.  Mutations in RYR1 in malignant hyperthermia and central core disease.

Authors:  Rachel Robinson; Danielle Carpenter; Marie-Anne Shaw; Jane Halsall; Philip Hopkins
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

Review 5.  Myopathology in congenital myopathies.

Authors:  C A Sewry; C Wallgren-Pettersson
Journal:  Neuropathol Appl Neurobiol       Date:  2017-02       Impact factor: 8.090

6.  Analysis of human cultured myotubes responses mediated by ryanodine receptor 1.

Authors:  M Kobayashi; K Mukaida; T Migita; H Hamada; M Kawamoto; O Yuge
Journal:  Anaesth Intensive Care       Date:  2011-03       Impact factor: 1.669

Review 7.  Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved.

Authors:  Guillermo Avila
Journal:  Cell Calcium       Date:  2005-02       Impact factor: 6.817

8.  Predicting functional effect of human missense mutations using PolyPhen-2.

Authors:  Ivan Adzhubei; Daniel M Jordan; Shamil R Sunyaev
Journal:  Curr Protoc Hum Genet       Date:  2013-01

9.  RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice.

Authors:  William J Durham; Paula Aracena-Parks; Cheng Long; Ann E Rossi; Sanjeewa A Goonasekera; Simona Boncompagni; Daniel L Galvan; Charles P Gilman; Mariah R Baker; Natalia Shirokova; Feliciano Protasi; Robert Dirksen; Susan L Hamilton
Journal:  Cell       Date:  2008-04-04       Impact factor: 41.582

10.  Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees.

Authors:  M Davis; R Brown; A Dickson; H Horton; D James; N Laing; R Marston; M Norgate; D Perlman; N Pollock; K Stowell
Journal:  Br J Anaesth       Date:  2002-04       Impact factor: 9.166

View more
  2 in total

Review 1.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

2.  Effects of Remimazolam and Propofol on Ca2+ Regulation by Ryanodine Receptor 1 with Malignant Hyperthermia Mutation.

Authors:  Tomoyuki Watanabe; Hirotsugu Miyoshi; Yuko Noda; Soshi Narasaki; Atsushi Morio; Yukari Toyota; Hiroshi Kimura; Keiko Mukaida; Toshimichi Yasuda; Yasuo M Tsutsumi
Journal:  Biomed Res Int       Date:  2021-01-04       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.